For the roughly 2.8 million people worldwide living with multiple sclerosis, the disease has already been silently reshaping immune biology for years before the first clinical symptom. A new proteogenomic analysis challenges the assumption that MS is detectable only after damage begins — and points toward a blood-based early warning system grounded in measurable molecular signals.
Using Mendelian randomization and colocalization across genetic data from more than 2,500 plasma proteins, investigators identified 39 proteins causally linked to MS susceptibility. These proteins do not cluster randomly; they form a tightly interconnected network concentrated in immune regulatory pathways — particularly B-cell and T-cell costimulation, cytokine signaling, and Epstein-Barr virus-associated biology. Transcriptomic enrichment was most pronounced in B-cell subsets, reinforcing EBV's suspected role as a molecular trigger. Crucially, eight of these proteins were measurable at significantly abnormal levels in UK Biobank blood samples drawn a median of nearly six years before MS diagnosis, demonstrating that the biological preclinical window is both real and detectable.
This work sits at the intersection of two accelerating fields — proteomics and causal inference via Mendelian randomization — and its implications extend well beyond neurology. The EBV-immune axis finding dovetails with the landmark 2022 Bjornevik cohort study establishing EBV as a near-necessary precursor to MS, and now adds a protein-level mechanistic layer to that association. For health-conscious adults, particularly those with family history or early demyelinating symptoms, this raises the prospect of clinically actionable pre-diagnostic screening — though that application remains speculative. Several important limitations apply: the prediagnostic validation cohort comprised only 124 cases, the analysis is largely genetic and observational rather than interventional, and protein measurement discrepancies across platforms introduce interpretive complexity. This is incremental but directionally significant work — the kind that, if replicated in larger prospective cohorts, could eventually reframe MS from a disease diagnosed at crisis to one intercepted at predisposition.